Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb Company and Gilead Sciences have reported that Health Canada has approved Atripla, the first once-daily single tablet regimen, as a stand-alone therapy or in combination with other antiretrovirals for the treatment of HIV-1 infection in adults.
Subscribe to our email newsletter
Atripla (efavirenz 600mg/emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) was developed through a joint venture partnership between Bristol-Myers Squibb and Gilead Sciences. Atripla combines sustiva (efavirenz) manufactured by Bristol-Myers Squibb, and truvada (emtricitabine/tenofovir disoproxil fumarate) manufactured by Gilead Sciences.
Mark Wainberg, director of the McGill AIDS Centre and professor of medicine and microbiology at McGill University, said: “Atripla represents a milestone in treatment for this disease. I commend the companies involved for joining forces to make Atripla, the first complete three-drug regimen in a single once-daily pill.”